Merck & Company Inc (MRK)vsNewGenIvf Group Limited Class A Ordinary Shares (NIVF)
MRK
Merck & Company Inc
$109.18
-1.60%
HEALTHCARE · Cap: $274.03B
NIVF
NewGenIvf Group Limited Class A Ordinary Shares
$1.72
-6.01%
HEALTHCARE · Cap: $1.11M
Smart Verdict
WallStSmart Research — data-driven comparison
Merck & Company Inc generates 1375387% more annual revenue ($65.01B vs $4.73M). NIVF leads profitability with a 209.0% profit margin vs 28.1%. NIVF trades at a lower P/E of 0.1x. MRK earns a higher WallStSmart Score of 59/100 (C).
MRK
Buy59
out of 100
Grade: C
NIVF
Buy57
out of 100
Grade: C
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-13.2%
Fair Value
$96.48
Current Price
$109.18
$12.70 premium
Intrinsic value data unavailable for NIVF.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 37 in profit
Strong operational efficiency at 32.8%
Keeps 28 of every $100 in revenue as profit
Attractively priced relative to earnings
Generating 1.8B in free cash flow
Attractively priced relative to earnings
Reasonable price relative to book value
Every $100 of equity generates 79 in profit
Keeps 209 of every $100 in revenue as profit
Areas to Watch
Weak financial health signals
Expensive relative to growth rate
Earnings declined 19.3%
0.0% earnings growth
Smaller company, higher risk/reward
Operating margin of -349.1%
Comparative Analysis Report
WallStSmart ResearchBull Case : MRK
The strongest argument for MRK centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 28.1% and operating margin at 32.8%.
Bull Case : NIVF
The strongest argument for NIVF centers on P/E Ratio, Price/Book, Return on Equity. Profitability is solid with margins at 209.0% and operating margin at -349.1%. Revenue growth of 11.9% demonstrates continued momentum.
Bear Case : MRK
The primary concerns for MRK are Piotroski F-Score, PEG Ratio, EPS Growth.
Bear Case : NIVF
The primary concerns for NIVF are EPS Growth, Market Cap, Operating Margin.
Key Dynamics to Monitor
MRK profiles as a value stock while NIVF is a mature play — different risk/reward profiles.
MRK carries more volatility with a beta of 0.28 — expect wider price swings.
NIVF is growing revenue faster at 11.9% — sustainability is the question.
Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.
Bottom Line
MRK scores higher overall (59/100 vs 57/100), backed by strong 28.1% margins. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Merck & Company Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.
Visit Website →NewGenIvf Group Limited Class A Ordinary Shares
HEALTHCARE · MEDICAL CARE FACILITIES · USA
NewGenIvf Group Limited (NIVF) is a leading entity in the reproductive health industry, focusing on cutting-edge fertility solutions and sophisticated in vitro fertilization (IVF) services. With a commitment to increasing success rates in assisted reproductive techniques, NIVF is strategically positioned to meet the rising global demand for fertility treatments through an established clinic network and key partnerships. As the market for fertility services continues to expand, the company is poised for significant growth, reinforcing its dedication to helping individuals and couples achieve their aspirations of parenthood.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?